BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Mycobacterium tuberculosis transmembrane transport protein 3 (MmpL3)

...Infectious disease INDICATION: Tuberculosis In vitro, cell culture and mouse studies identified a carboxamide-based MmpL3 inhibitor...
...steps could include testing the safety of the compounds in animal models of TB. TARGET/MARKER/PATHWAY: Mycobacterium tuberculosis transmembrane transport protein 3 (MmpL3)...
BioCentury | Sep 1, 2014
Company News

Novartis, TB Alliance deal

...NITD). The portfolio includes a group of indolcarboxamide candidates, including NITD304 , an inhibitor of mycobacterium tuberculosis transmembrane transport protein 3 (MmpL3)...
BioCentury | Aug 21, 2014
Company News

TB Alliance gains Novartis tuberculosis portfolio

...Diseases (NITD). The portfolio includes a group of indolcarboxamide candidates including NITD304, an inhibitor of mycobacterium tuberculosis transmembrane transport protein 3 (MmpL3)...
BioCentury | Nov 7, 2013
Distillery Therapeutics

Indication: Infectious disease

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis Mycobacterium tuberculosis transmembrane transport protein 3 (mmpL3) In vitro and...
...and solubility and publication of further details of how the compounds inhibit their proposed target, mmpL3...
Items per page:
1 - 4 of 4